Exploring the anti-aging effects of Metformin in COPD

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Brief summary

Change in FEV1 at baseline and 3-year follow-up.

Detailed description

Age, Sex at birth, Height, Baseline weight and annually until the end of follow-up., Baseline smoking status., Blood tests at baseline and annually until the end of follow-up., Urinalysis with baseline renal function and annually until the end of follow-up., Baseline and 3-year microbiota analysis., Percentage of lung volume affected with emphysema at baseline and 3-year follow-up., COPD assessment test (CAT), baseline and every 6 months until the end of follow-up., mMRC scale at baseline and annually until the end of follow-up., St. George's Respiratory Questionnaire (SGRQ), baseline and every 6 months until the end of follow-up., Concomitant respiratory treatment, baseline and every 6 months until the end of follow-up., Number of annual exacerbations, doctor visits, hospitalisations., BODE index at baseline and annually until the end of follow-up., 6 minutes walking test (6MWD) at baseline and annually until the end of follow-up., Hand grip strength of the dominant hand baseline and annually until the end of follow-up., Incidence of lung cancer and other solid tumours throughout follow-up., Incidence of myocardial infarction, new angina, stroke, renal failure throughout follow-up.

Related papers

No related papers found yet.

Interventions

DRUGMetformina Uxa 850 mg comprimidos recubiertos con película EFG

DRUGEl producto denominado Placebo Metformina comprimidos recubiertos está constituido por comprimidos recubiertos blancos que contienen celulosa microcristalina Ph Eur

DRUGacondicionados en blisters de PVC/PE/PVDC transparente con aluminio anónimo.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in FEV1 at baseline and 3-year follow-up.	—

Secondary

Measure	Time frame
Age, Sex at birth, Height, Baseline weight and annually until the end of follow-up., Baseline smoking status., Blood tests at baseline and annually until the end of follow-up., Urinalysis with baseline renal function and annually until the end of follow-up., Baseline and 3-year microbiota analysis., Percentage of lung volume affected with emphysema at baseline and 3-year follow-up., COPD assessment test (CAT), baseline and every 6 months until the end of follow-up., mMRC scale at baseline and annually until the end of follow-up., St. George's Respiratory Questionnaire (SGRQ), baseline and every 6 months until the end of follow-up., Concomitant respiratory treatment, baseline and every 6 months until the end of follow-up., Number of annual exacerbations, doctor visits, hospitalisations., BODE index at baseline and annually until the end of follow-up., 6 minutes walking test (6MWD) at baseline and annually until the end of follow-up., Hand grip strength of the dominant hand baseline and	—

Measure

Time frame

Age, Sex at birth, Height, Baseline weight and annually until the end of follow-up., Baseline smoking status., Blood tests at baseline and annually until the end of follow-up., Urinalysis with baseline renal function and annually until the end of follow-up., Baseline and 3-year microbiota analysis., Percentage of lung volume affected with emphysema at baseline and 3-year follow-up., COPD assessment test (CAT), baseline and every 6 months until the end of follow-up., mMRC scale at baseline and annually until the end of follow-up., St. George's Respiratory Questionnaire (SGRQ), baseline and every 6 months until the end of follow-up., Concomitant respiratory treatment, baseline and every 6 months until the end of follow-up., Number of annual exacerbations, doctor visits, hospitalisations., BODE index at baseline and annually until the end of follow-up., 6 minutes walking test (6MWD) at baseline and annually until the end of follow-up., Hand grip strength of the dominant hand baseline and

—

Countries

Spain

Outcome results

None listed